"Calculation was based on the analysis of data of volunteers, who received both the first and second doses of the Sputnik V vaccine or placebo at the third and final control point of 78 confirmed cases in accordance with the Phase III clinical trials protocol," the statement informs.
Meanwhile, the vaccine demonstrated 100 % efficacy against severe coronavirus cases. There were 20 severe cases of coronavirus infection among confirmed cases in the placebo group and no severe cases in the vaccine group.
As of December 14, more than 26,000 volunteers were vaccinated at 29 medical centers in Russia as part of its ongoing clinical trials.
According to developers, cost of one dose of the vaccine is less than $10 for international markets while the production of the lyophilized (dry) form of the vaccine, which is stored at a temperature of +2 to +8 degrees Celsius, enables easier distribution of the vaccine in international markets.
UK and Russian scientists intend to trial a combination of the Oxford-AstraZeneca and Sputnik V vaccines to see if protection against Covid-19 can be improved.
AstraZeneca reported it was evaluating how to assess combinations of different vaccines, and one of those combinations was with the Russian Sputnik V. Specifically, they are considering vaccines that use similar technology as their own, which is the case with the Sputnik V vaccine—both use common cold viruses as vectors, unlike the Pfizer-BioNTech and Moderna vaccines, which use mRNA encapsulated in nanolipid particles.